Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

Brian I. Rini, MD
Published: Wednesday, Jul 05, 2017



Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

The next wave with adjuvant treatment in RCC is checkpoint inhibitors, Rini explains. There are handful of ongoing clinical trials exploring them in this setting, one of which is with atezolizumab (Tecentriq). Other ongoing studies are with nivolumab (Opdivo) and durvalumab (Imfinzi).

Immunotherapy makes sense in the adjuvant setting, Rini adds, because it is usually better tolerated by patients and likely has the potential to extend overall survival. However, the results of these ongoing trials won't be available for many years, he concludes.
 


Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

The next wave with adjuvant treatment in RCC is checkpoint inhibitors, Rini explains. There are handful of ongoing clinical trials exploring them in this setting, one of which is with atezolizumab (Tecentriq). Other ongoing studies are with nivolumab (Opdivo) and durvalumab (Imfinzi).

Immunotherapy makes sense in the adjuvant setting, Rini adds, because it is usually better tolerated by patients and likely has the potential to extend overall survival. However, the results of these ongoing trials won't be available for many years, he concludes.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x